Table 1.
Demographics and Baseline Patient and Disease Characteristics in the Intent-to-Treat Population
| Characteristic | Dalbavancin Treatment |
|
|---|---|---|
| Single-Dose (n = 349) | 2-Dose (n = 349) | |
| Age, y, mean (SD) | 48.0 (14.8) | 48.3 (14.7) |
| Female sex | 145 (41.5) | 146 (41.8) |
| Race | ||
| White | 312 (89.4) | 311 (89.1) |
| Black or African American | 28 (8.0) | 31 (8.9) |
| Other | 9 (2.6) | 7 (2.0) |
| Hepatitis C | 49 (14.0) | 64 (18.3) |
| Current or former intravenous drug use, % | 105 (30.1) | 107 (30.7) |
| Diabetes | 38 (10.9) | 42 (12.0) |
| BMI, kg/m2 | ||
| Mean (SD) | 28.7 (7.5) | 29.0 (7.3) |
| Median (Min, Max) | 26.9 (15.9, 70.6) | 27.8 (17.9, 65.5) |
| BMI distribution | ||
| <25 kg/m2 | 115 (33.0) | 122 (35.0) |
| 25–30 kg/m2 | 123 (35.2) | 99 (28.4) |
| >30 kg/m2 | 111 (31.8) | 128 (36.7) |
| Location of trial center | ||
| North America | 158 (45.3) | 160 (45.8) |
| Rest of world | 191 (54.7) | 189 (54.2) |
| Cellulitis | 167 (47.9) | 166 (47.6) |
| Major abscess | 86 (24.6) | 89 (25.5) |
| Traumatic wound/surgical site infection | 96 (27.5) | 94 (26.9) |
| White blood cell count >12 000 cells/µL | 132 (37.9) | 126 (36.8) |
| Temperature ≥38°C at baseline | 290 (83.1) | 283 (81.8) |
| Immature neutrophils ≥10% | 56 (21.3) | 46 (17.2) |
| Median infection area, cm2 (range) | 296.1 (56.0–4235.0) | 293.3 (76.5–2668.0) |
| Systemic inflammatory response syndrome | 148 (42.4) | 154 (44.4) |
| Pathogen at baseline | 210 (60.2) | 220 (63.0) |
| MRSA, no./No. (%)* | 36/210 (17.1) | 61/220 (27.7) |
| MSSA, no./No. (%) | 103/210 (49.0) | 96/220 (43.6) |
| Gram-negative aerobic organism, no./No. (%) | 19/210 (9.0) | 28/220 (12.7) |
Data are presented as No. (%) unless otherwise specified.
Abbreviations: BMI, body mass index; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; SD, standard deviation.
* P = .011.